162 related articles for article (PubMed ID: 36470859)
1. Proteogenomic characterization of MiT family translocation renal cell carcinoma.
Qu Y; Wu X; Anwaier A; Feng J; Xu W; Pei X; Zhu Y; Liu Y; Bai L; Yang G; Tian X; Su J; Shi GH; Cao DL; Xu F; Wang Y; Gan HL; Ni S; Sun MH; Zhao JY; Zhang H; Ye D; Ding C
Nat Commun; 2022 Dec; 13(1):7494. PubMed ID: 36470859
[TBL] [Abstract][Full Text] [Related]
2. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
[TBL] [Abstract][Full Text] [Related]
3. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
[TBL] [Abstract][Full Text] [Related]
4. Racial Disparities in MiT Family Translocation Renal Cell Carcinoma.
Lu X; Tawanaie Pour Sedehi N; Su X; Yan F; Alhalabi O; Tannir NM; Malouf GG
Oncologist; 2023 Nov; 28(11):1009-1013. PubMed ID: 37315151
[TBL] [Abstract][Full Text] [Related]
5. Dual role of G-quadruplex in translocation renal cell carcinoma: Exploring plausible Cancer therapeutic innovation.
Neha ; Das P; Verma SP
Biochim Biophys Acta Gen Subj; 2020 Dec; 1864(12):129719. PubMed ID: 32882363
[TBL] [Abstract][Full Text] [Related]
6. [MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management].
Herrscher H; Boilève A; Lindner V; Barthélémy P; Hutt É; Pierard L; Kurtz JE; Rioux-Leclercq N; Lang H; Malouf GG
Bull Cancer; 2020 Feb; 107(2):272-280. PubMed ID: 32044098
[TBL] [Abstract][Full Text] [Related]
7. MiT translocation renal cell carcinoma: A review of the literature from molecular characterization to clinical management.
Rizzo M; Pezzicoli G; Santoni M; Caliò A; Martignoni G; Porta C
Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188823. PubMed ID: 36240899
[TBL] [Abstract][Full Text] [Related]
8. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of NMRK2 mediated by TFE3 fusions is the key for energy metabolism adaption of Xp11.2 translocation renal cell carcinoma.
Chen Y; Yang L; Lu Y; Liu N; Ma W; Fan H; Hu Q; Han X; Gan W; Li D
Cancer Lett; 2022 Jul; 538():215689. PubMed ID: 35447281
[TBL] [Abstract][Full Text] [Related]
11. Translocation renal cell carcinomas: an evolving entity and a member of the microphthalmia transcription factor-associated family of tumors.
Bambury RM; Battley JE; McCarthy A; Brady C; O'Reilly S; Kelly PJ; O'Brien F; Sweeney P; Fleming S; Mayer NJ; Power DG
Clin Genitourin Cancer; 2013 Sep; 11(3):357-61. PubMed ID: 23332637
[No Abstract] [Full Text] [Related]
12. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
[TBL] [Abstract][Full Text] [Related]
13. Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents.
Cao C; Lan X; Shang B; Jiang W; Guo L; Zheng S; Bi X; Zhou A; Sun Z; Shou J
Clin Transl Oncol; 2022 Jul; 24(7):1333-1346. PubMed ID: 35118587
[TBL] [Abstract][Full Text] [Related]
14. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis-A Systematic Review and Pooled Analysis.
Wu Y; Chen S; Zhang M; Liu K; Jing J; Pan K; Zhang L; Xu B; Lu X; Chen M
Pathol Oncol Res; 2021; 27():610360. PubMed ID: 34257577
[No Abstract] [Full Text] [Related]
16. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
[TBL] [Abstract][Full Text] [Related]
17. MiT family translocation-associated (TFE3 positive) renal cell carcinoma of childhood.
Katiyar R; U Patne SC; Chowdhary S
Indian J Pathol Microbiol; 2018; 61(4):620-622. PubMed ID: 30303168
[No Abstract] [Full Text] [Related]
18. MiT/TFE Family Renal Cell Carcinoma.
Tang J; Baba M
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672892
[TBL] [Abstract][Full Text] [Related]
19. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.
Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W
Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181
[TBL] [Abstract][Full Text] [Related]
20. Genomic heterogeneity of translocation renal cell carcinoma.
Malouf GG; Monzon FA; Couturier J; Molinié V; Escudier B; Camparo P; Su X; Yao H; Tamboli P; Lopez-Terrada D; Picken M; Garcia M; Multani AS; Pathak S; Wood CG; Tannir NM
Clin Cancer Res; 2013 Sep; 19(17):4673-84. PubMed ID: 23817689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
